Egetis Therapeutics Valuation

Is 0ABW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0ABW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

SEK 124.42

Fair Value

94.8% undervalued

Number of Analysts

Below Fair Value: 0ABW (SEK6.43) is trading below our estimate of fair value (SEK124.42)

Significantly Below Fair Value: 0ABW is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0ABW?

Key metric: As 0ABW is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0ABW. This is calculated by dividing 0ABW's market cap by their current revenue.
What is 0ABW's PS Ratio?
PS Ratio	33.3x
Sales	SEK 67.90m
Market Cap	SEK 2.26b

0ABW key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	33.1x
Enterprise Value/EBITDA	-7.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0ABW's PS Ratio compare to its peers?

The above table shows the PS ratio for 0ABW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.7x
BVXP Bioventix	12.5x	n/a	UK£169.6m
AVCT Avacta Group	8.3x	0.4%	UK£186.6m
TRX Tissue Regenix Group	1.6x	15.1%	UK£41.7m
OXB Oxford Biomedica	4.5x	21.2%	UK£434.3m
0ABW Egetis Therapeutics	33.3x	91.5%	SEK 2.3b

Price-To-Sales vs Peers: 0ABW is expensive based on its Price-To-Sales Ratio (33.3x) compared to the peer average (6.7x).

Price to Sales Ratio vs Industry

How does 0ABW's PS Ratio compare vs other companies in the GB Biotechs Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.5x	3.7%	US$1.19b
TRX Tissue Regenix Group	1.6x	15.1%	US$50.89m
VRCI Verici Dx	3.5x	78.8%	US$15.11m
DEST Destiny Pharma	3.5x	-171.4%	US$5.85m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 0ABW is expensive based on its Price-To-Sales Ratio (33.3x) compared to the European Biotechs industry average (8.2x).

Price to Sales Ratio vs Fair Ratio

What is 0ABW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0ABW PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	33.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0ABW's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0ABW forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 6.43	SEK 11.50 +78.8%	26.9%	SEK 15.00	SEK 6.00	n/a	6
Jan ’26	SEK 7.04	SEK 11.50 +63.4%	26.9%	SEK 15.00	SEK 6.00	n/a	6
Dec ’25	SEK 5.30	SEK 10.80 +103.8%	25.8%	SEK 14.00	SEK 6.00	n/a	5
Nov ’25	n/a	SEK 11.40 0%	26.4%	SEK 15.00	SEK 6.00	n/a	5
Oct ’25	SEK 4.66	SEK 11.40 +144.6%	26.4%	SEK 15.00	SEK 6.00	n/a	5
Sep ’25	SEK 5.80	SEK 11.40 +96.6%	26.4%	SEK 15.00	SEK 6.00	n/a	5
Aug ’25	SEK 5.83	SEK 13.30 +128.1%	32.7%	SEK 18.00	SEK 6.00	n/a	5
Jul ’25	SEK 4.73	SEK 13.30 +181.5%	32.7%	SEK 18.00	SEK 6.00	n/a	5
Jun ’25	SEK 8.71	SEK 14.30 +64.2%	20.2%	SEK 18.00	SEK 11.00	n/a	5
May ’25	SEK 5.94	SEK 13.13 +120.9%	19.5%	SEK 17.50	SEK 11.00	n/a	4
Apr ’25	SEK 6.69	SEK 13.13 +96.2%	19.5%	SEK 17.50	SEK 11.00	n/a	4
Mar ’25	SEK 6.61	SEK 13.13 +98.5%	19.5%	SEK 17.50	SEK 11.00	n/a	4
Feb ’25	SEK 5.79	SEK 12.75 +120.2%	15.1%	SEK 16.00	SEK 11.00	n/a	4
Jan ’25	SEK 5.52	SEK 11.10 +101.1%	32.0%	SEK 16.00	SEK 5.00	SEK 7.04	5
Dec ’24	SEK 4.77	SEK 11.10 +132.7%	32.0%	SEK 16.00	SEK 5.00	SEK 5.30	5
Nov ’24	SEK 4.99	SEK 11.10 +122.7%	32.0%	SEK 16.00	SEK 5.00	n/a	5
Oct ’24	SEK 4.49	SEK 11.10 +147.2%	32.0%	SEK 16.00	SEK 5.00	SEK 4.66	5
Sep ’24	n/a	SEK 11.10 0%	32.0%	SEK 16.00	SEK 5.00	SEK 5.80	5
Aug ’24	SEK 4.34	SEK 11.50 +165.3%	36.1%	SEK 18.00	SEK 5.00	SEK 5.83	5
Jul ’24	SEK 4.45	SEK 13.90 +212.4%	18.5%	SEK 18.00	SEK 10.50	SEK 4.73	5
Jun ’24	SEK 4.95	SEK 14.50 +193.2%	14.5%	SEK 18.00	SEK 11.50	SEK 8.71	5
May ’24	SEK 8.55	SEK 16.50 +93.0%	26.0%	SEK 24.00	SEK 11.50	SEK 5.94	5
Apr ’24	SEK 7.80	SEK 16.50 +111.5%	26.0%	SEK 24.00	SEK 11.50	SEK 6.69	5
Mar ’24	SEK 5.22	SEK 14.63 +180.2%	15.9%	SEK 18.00	SEK 11.50	SEK 6.61	4
Feb ’24	SEK 6.11	SEK 15.67 +156.4%	10.8%	SEK 18.00	SEK 14.00	SEK 5.79	3
Jan ’24	n/a	SEK 17.75 0%	22.0%	SEK 24.00	SEK 14.00	SEK 5.52	4

Analyst Price Target

Consensus Narrative from 6 Analysts

SEK 11.74

Fair Value

45.2% undervalued

Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 10:13
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Egetis Therapeutics AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Patrick Langstrom	ABG Sundal Collier Sponsored
Oscar Haffen Lamm	Bryan Garnier & Co